Experimental drug shows promise for tough skin cancer
NCT ID NCT00249262
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a weekly injection of a new chemotherapy drug called Taxoprexin in 30 people with advanced melanoma that had spread to other parts of the body. The goal was to see if the drug could shrink tumors and how long that effect might last. Researchers also monitored side effects and overall survival. Participants had not received chemotherapy before for their metastatic disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a One-Two punch of immune boosters revive cancer treatment?
- Could a personal coach at home boost energy for cancer patients?
- Morning vs. afternoon: could the clock boost immunotherapy against melanoma?
- Could a common vaccine supercharge immunotherapy against melanoma?
- Engineered immune cells take aim at Hard-to-Treat cancers
- New drug cocktail targets rare, aggressive melanoma